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Supplementary Figure 1: Risks and burdens of Post-Acute Sequelae of SARS-CoV-2 infection (PASC) after 12 weeks. Hazard ratio and 95% 
confidence intervals were are presented in left panel and burdens per 1000 COVID-19 patients at 6-months are presented in right panel 
 
 












Supplementary Table 1: Unadjusted number and percentage of incident clinical manifestations during the follow up in 1) users of Veterans Health 
Administration (VHA) without COVID-19, 2) Overall COVID-19 patients, 3) non-hospitalized COVID-19 patients, 4) hospitalized COVID-19 patients, 
and 5) COVID-19 patients admitted to intensive care 
Organ  Clinical manifestation VHA users 
 
Unadjusted 























number of events 
(%) 
Cardiovascular  Acute coronary disease 60217 (1.54) 3694 (2.36) 2332 (1.7) 910 (6.14) 452 (10.01) 
Arrythmias 33623 (0.78) 3073 (1.77) 2217 (1.48) 561 (3.12) 295 (5.41) 
Bradycardia 14729 (0.34) 1297 (0.73) 787 (0.51) 327 (1.76) 183 (3.16) 
Chest pain 54552 (1.29) 5270 (3.16) 3897 (2.69) 1027 (6.22) 346 (6.67) 
Heart failure 11862 (0.27) 1464 (0.82) 643 (0.42) 532 (2.91) 289 (5.17) 
Myocarditis 125 (0) 73 (0.04) 30 (0.02) 26 (0.13) 17 (0.28) 
Tachycardia 12497 (0.29) 1710 (0.96) 885 (0.57) 511 (2.75) 314 (5.45) 
Coagulation Thromboembolism 15795 (0.36) 2771 (1.57) 1423 (0.93) 821 (4.48) 527 (9.23) 
Dermatologic  Hair loss 2050 (0.05) 244 (0.13) 204 (0.13) 31 (0.16) 9 (0.15) 
Skin rash 33188 (0.77) 2333 (1.33) 1790 (1.19) 402 (2.18) 141 (2.45) 
Endocrine  Diabetes mellitus 61533 (1.83) 3570 (2.91) 2709 (2.48) 592 (5.64) 269 (8.91) 
Hyperlipidemia 254134 (7.84) 12959 (10.82) 11056 (10.74) 1377 (10.65) 526 (13.38) 
Obesity 78868 (1.98) 5496 (3.58) 4327 (3.26) 793 (5) 376 (7.71) 
Gastrointestinal  Constipation 38889 (0.91) 3658 (2.13) 2187 (1.46) 1019 (5.91) 452 (8.4) 
Diarrhea 25255 (0.58) 2363 (1.36) 1534 (1.02) 563 (3.13) 266 (4.69) 
GERD 110376 (3) 6965 (4.9) 5182 (4.19) 1272 (8.98) 511 (11.68) 
General Fatigue 39788 (0.93) 4962 (2.89) 2631 (1.76) 1553 (9.3) 778 (14.88) 
Kidney  Acute kidney injury 23875 (0.55) 3307 (1.89) 1237 (0.81) 1257 (7.31) 813 (15.49) 
Chronic kidney disease 131914 (3.47) 5662 (3.82) 4486 (3.41) 876 (6.73) 300 (7.70) 
Mental health  Anxiety 46434 (1.15) 4239 (2.67) 2625 (1.9) 985 (6.29) 629 (12.77) 
Depression 60262 (1.47) 4531 (2.8) 3167 (2.26) 999 (6.08) 365 (7.01) 
Mood disorder 56112 (1.4) 3708 (2.34) 2886 (2.11) 600 (3.58) 222 (4.19) 
Sleep disorder 135989 (4) 8995 (7.44) 7037 (6.71) 1417 (11.45) 541 (14.59) 
Substance abuse 85234 (2.21) 4134 (2.65) 3165 (2.33) 689 (4.47) 280 (5.7) 
Musculoskeletal  Joint pain 108830 (2.84) 6873 (4.67) 5097 (3.96) 1273 (9.01) 503 (11.51) 
Muscle weakness 26763 (0.62) 3703 (2.12) 1817 (1.19) 1249 (7.19) 637 (11.79) 
 
Neurologic  Headache 41186 (0.98) 3161 (1.89) 2573 (1.79) 429 (2.4) 159 (2.84) 
Memory problems 32078 (0.75) 2769 (1.63) 1564 (1.05) 821 (4.92) 384 (7.23) 
Smell problems 1691 (0.04) 356 (0.2) 279 (0.18) 49 (0.25) 28 (0.46) 
Stroke 16888 (0.39) 1456 (0.83) 880 (0.58) 380 (2.1) 196 (3.44) 
Pulmonary  Cough 28088 (0.66) 3041 (1.83) 2290 (1.59) 536 (3.13) 215 (4.04) 
Hypoxemia 9067 (0.21) 2017 (1.13) 890 (0.58) 700 (3.72) 427 (7.37) 
Shortness of breath 58454 (1.38) 7627 (4.58) 5176 (3.56) 1653 (10.2) 798 (16.03) 
Unadjusted number and percentage of incident clinical manifestation during the follow up are obtained within participants without the occurrence of 


















Supplementary Table 2: Risks and burdens of individual sequela in 30-day survivors of COVID-19 
Organ  Sequelae  Hazard Ratio 
(95% CI) 
Burden per 1000 persons at 6 months  
(95% CI) 
Cardiovascular  Chest pain 1.68 (1.62, 1.73) 13.84 (12.86, 14.76) 
Arrythmias 1.59 (1.52, 1.66) 7.85 (7.08, 8.58) 
Acute coronary disease 1.30 (1.25, 1.35) 6.18 (5.37, 6.96) 
Tachycardia 1.77 (1.65, 1.89) 4.69 (4.18, 5.21) 
Bradycardia 1.42 (1.32, 1.51) 2.63 (2.14, 3.1) 
Heart failure 1.40 (1.30, 1.5) 2.02 (1.67, 2.37) 
Myocarditis 7.91 (5.27, 11.53) 0.32 (0.23, 0.45) 
Coagulation Thromboembolism 2.59 (2.46, 2.72) 11.35 (10.59, 12.12) 
Dermatologic  Skin rash 1.27 (1.21, 1.33) 3.3 (2.67, 3.89) 
Hair loss 1.93 (1.54, 2.37) 0.22 (0.17, 0.29) 
Endocrine  Hyperlipidemia 1.22 (1.19, 1.24) 17.09 (15.28, 18.79) 
Diabetes mellitus 1.39 (1.33, 1.44) 8.47 (7.46, 9.44) 
Obesity 1.28 (1.24, 1.32) 3.49 (3.06, 3.92) 
Gastrointestinal  GERD 1.33 (1.3, 1.37) 13.25 (11.97, 14.49) 
Constipation 1.41 (1.35, 1.47) 7.13 (6.33, 7.9) 
Diarrhea 1.48 (1.41, 1.56) 4.68 (4.09, 5.27) 
General Fatigue 1.75 (1.68, 1.81) 13.59 (12.66, 14.49) 
Kidney 
 
Chronic kidney disease 1.18 (1.13, 1.23) 7.19 (5.78, 8.55) 
Acute kidney injury 1.41 (1.34, 1.48) 6.07 (5.46, 6.69) 
Mental health  Sleep disorders 1.41 (1.37, 1.44) 19.51 (18.05, 20.92) 
Anxiety 1.47 (1.41, 1.53) 8.75 (7.96, 9.55) 
Depression 1.37 (1.32, 1.42) 7.61 (6.8, 8.42) 
Mood disorder 1.31 (1.26, 1.36) 4.57 (3.93, 5.21) 
Substance abuse 1.16 (1.12, 1.2) 3.24 (2.55, 3.92) 
Musculoskeletal  Muscle weakness 1.82 (1.74, 1.9) 9.81 (9.05, 10.55) 
Joint pain 1.21 (1.18, 1.24) 8.92 (7.67, 10.1) 
Neurologic  Memory problems 1.56 (1.48, 1.63) 6.46 (5.78, 7.13) 
Headache 1.39 (1.33, 1.44) 3.8 (3.32, 4.28) 
Stroke 1.5 (1.4, 1.59) 3.11 (2.6, 3.59) 
Smell problems 3.61 (3.15, 4.11) 1.34 (1.13, 1.56) 
Pulmonary  Shortness of breath 2.23 (2.17, 2.29) 28.8 (27.55, 29.97) 
 
Cough 2.02 (1.93, 2.10) 10.24 (9.46, 10.98) 
Hypoxemia 2.83 (2.65, 3.01) 6.43 (5.94, 6.93) 
Adjusted hazard ratio, adjusted burden per 1000 persons at 6 months of people with COVID-19 compared to users of the 
Veterans Health Administration. All users of the VHA served as the referent category. Outcomes were ascertained from day 30 
after COVID-19 diagnosis until end of follow-up. For each outcome, cohort participants without history of the outcome in past one 





















Supplementary Table 3: Unadjusted overall burden of Post-Acute Sequelae of SARS-CoV-2 infection (PASC) per 1000 persons at 6 months in the 
overall cohort and across care setting (non-hospitalized, hospitalized, and admitted to intensive care during the acute phase of the infection). 
 COVID-19 group 
Unadjusted burden 
per 1000 persons at 
6 months (95% CI) 
Users of the VHA 
without COVID-19 
Unadjusted burden 
per 1000 persons at 




per 1000 persons at 































*. Care settings during the first 30 days of infection. 
†. Burden defined as having at least one sequela in excess of users of the Veterans Health 
Administration without COVID-19 after the first 30-days of infection. Burden was estimated 












Supplementary Table 4: Adjusted burden of individual clinical manifestations per 1000 persons at 6 months in 1) users of Veterans Health 
Administration (VHA) without COVID-19, 2) Overall COVID-19 patients, 3) non-hospitalized COVID-19 patients, 4) hospitalized COVID-19 patients, 







per 1000 persons 
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per 1000 persons 
at 6 months  
(95% CI) 


















































 (38.13, 41.11) 
33.34 
































































































































































































































































































































Supplementary Table 5: Burden of Post-acute Sequelae of COVID-19 individual sequelae in the overall cohort and by age, race, sex, and health 
status 
Organ  Sequelae  Overall Age Race 
























































































































































































































































Pulmonary Hypoxemia 6.43 2.72 6.89 10.25 5.92 6.84 
 


























































































































































































































Organ  Sequelae  Overall Sex Comorbidity 


































































































































































































































































































































Mental Mood 4.57 4.71 4.39 3.87 4.14 7.1 
 













































































































































Post-acute sequelae were ascertained from 30 days after infection until end of follow-up. 












Supplementary Table 6: Differences in burden of individual Post-acute Sequelae of COVID-19 by age, race, sex, and health status in the overall 
cohort 
Organ  Sequelae  
Age >70 compare to 
Age ≤60 
Black compared to 
White 
Male compared to 
Female 
High comorbidity 
compared to low 
comorbidity 
Kidney Acute kidney injury 11.00 (9.66, 12.38) 4.06 (2.49, 5.73) 5.63 (4.45, 6.73) 22.50 (19.14, 25.95) 
Mental health Anxiety 7.31 (5.45, 9.21) 1.33 (-0.55, 3.26) 3.38 (0.58, 6.08) 13.55 (10.44, 16.79) 
Cardiovascular Bradycardia 2.73 (1.74, 3.81) -0.87 (-1.86, 0.26) 1.07 (-0.18, 2.2) 1.45 (-0.15, 3.22) 
Cardiovascular Chest pain -6.6 (-8.74, -4.54) 3.4 (0.96, 5.67) -4.51 (-7.99, -0.91) 1.65 (-1.59, 4.79) 
Kidney 
Chronic kidney 
disease 18.36 (14.43, 22.21) -0.89 (-3.71, 1.90) 4.5 (0.73, 8.13) 16.59 (10.10, 23.54) 
Gastrointestinal Constipation 9.76 (8.1, 11.52) 1.75 (-0.07, 3.7) 1.28 (-1.31, 4.02) 11.45 (8.44, 14.66) 
Pulmonary Cough -1.71 (-3.28, -0.12) 3 (1.32, 4.82) -3.25 (-5.9, -0.6) 1.2 (-1.07, 3.64) 
Mental health Depression -0.66 (-2.6, 1.29) 0.56 (-1.27, 2.43) 0.6 (-2.56, 3.65) 7.82 (5.07, 10.67) 
Gastrointestinal Diarrhea 0.18 (-1.11, 1.41) 0.54 (-0.8, 1.92) 0.15 (-2.02, 2.07) 5.5 (3.32, 7.82) 
Endocrine Diabetes mellitus 6.41 (4.21, 8.55) 4.04 (1.43, 6.53) 5.78 (3.41, 8.19) 2.52 (-2.44, 7.74) 
General Fatigue 17.39 (15.43, 19.41) 0.63 (-1.44, 2.85) 7.1 (4.47, 9.55) 26.45 (22.7, 30.45) 
Gastrointestinal Gerd 9.49 (6.61, 12.27) -3.01 (-5.91, -0.17) 7.56 (3.38, 11.59) 13.84 (9.56, 18.24) 
Dermatologic Hair loss -0.63 (-0.87, -0.41) -0.18 (-0.31, -0.03) -3.46 (-4.72, -2.31) -0.2 (-0.36, -0.02) 
Neurologic Headache -4.09 (-5.6, -2.5) 1.92 (0.63, 3.2) -7.94 (-10.88, -4.94) 0.4 (-1.28, 2.25) 
Cardiovascular Arrythmias -1.24 (-2.95, 0.38) -0.17 (-1.94, 1.55) -3.37 (-6.13, -0.73) 1.42 (-1.17, 3.86) 
Cardiovascular Heart failure 4.67 (3.87, 5.51) 0.09 (-0.71, 0.95) 1.93 (1.28, 2.51) 8.3 (6.36, 10.39) 
Endocrine Hyperlipidemia -8.5 (-12.92, -4.1) -2.47 (-6.43, 1.44) 5.85 (0.16, 11.94) -11.04 (-16.32, -5.93) 
Pulmonary Hypoxemia 7.53 (6.52, 8.6) -0.91 (-1.98, 0.22) 4.5 (3.42, 5.48) 12.81 (10.74, 15.01) 
Musculoskeletal Joint pain 4.92 (2.23, 7.65) 1.76 (-1.1, 4.54) 6.38 (2.63, 10.21) 10.1 (5.76, 14.66) 
Neurologic Memory problems 12.75 (11.06, 14.44) -0.96 (-2.34, 0.6) 4.92 (3.32, 6.54) 9.18 (6.67, 11.93) 
Cardiovascular 
Acute coronary 
disease 13.93 (11.87, 16.02) -0.83 (-2.52, 0.94) 7.05 (5.53, 8.35) 14.66 (11.03, 18.55) 
Mental health Mood disorder -1.98 (-3.82, -0.18) 1.56 (-0.05, 3.15) 0.34 (-2.24, 2.92) 3.29 (1.19, 5.51) 
Musculoskeletal Muscle weakness 16.96 (15.16, 18.69) 1.53 (-0.33, 3.39) 7.81 (5.75, 9.64) 24.47 (21, 28.02) 
Cardiovascular Myocarditis 0.07 (-0.14, 0.3) -0.02 (-0.23, 0.27) 0.34 (0.23, 0.48) 0.46 (0.17, 0.97) 
 
Endocrine Obesity -2.88 (-4.16, -1.68) -0.69 (-1.69, 0.26) -0.67 (-2.86, 1.38) 0.01 (-1.49, 1.55) 
Pulmonary Shortness of breath 4.28 (1.67, 6.92) 1.74 (-1.16, 4.71) -5.46 (-9.47, -1.41) 17.26 (13.1, 21.53) 
Dermatologic Skin rash 0.1 (-1.27, 1.54) -1.29 (-2.63, 0.08) -2.7 (-5.1, -0.41) -0.14 (-2.06, 1.9) 
Mental health Sleep disorder -5.59 (-9.45, -2) -3.22 (-6.5, 0.17) 5.19 (0.11, 9.96) 8.77 (3.69, 14.03) 
Neurologic Smell problems -1.27 (-1.8, -0.75) -0.54 (-0.97, -0.06) -0.41 (-1.14, 0.19) -0.45 (-0.99, 0.18) 
Neurologic Stroke 4.61 (3.53, 5.71) 0.57 (-0.6, 1.76) 1.83 (0.59, 2.94) 5.21 (3.28, 7.25) 
Mental health Substance abuse -0.83 (-2.34, 0.76) 2.92 (1.26, 4.73) 2.61 (0.82, 4.47) 1.13 (-1, 3.49) 
Cardiovascular Tachycardia 0.68 (-0.51, 1.8) 1.46 (0.17, 2.77) -0.68 (-2.5, 1.03) 5.34 (3.47, 7.31) 
Coagulation Thromboembolism 10.04 (8.34, 11.68) 2.71 (0.82, 4.56) 7.01 (4.97, 8.67) 11.46 (8.88, 14.2) 
















Supplementary Table 7: Burden of Post-acute Sequelae of COVID-19 individual sequelae in the overall cohort and by age, race, sex, and health 
status in non-hospitalized COVID-19 
Organ  Sequelae  Overall Age Race 
























































































































































































































































Pulmonary Hypoxemia 3.82 1.81 3.85 5.31 3.05 4.31 
 


























































































































































































































Organ  Sequelae  Overall Sex Comorbidity 


































































































































































































































































































































Mental Mood 2.94 2.97 3.67 3.09 2.25 3.7 
 













































































































































Post-acute sequelae were ascertained from 30 days after infection until end of follow-up. 











Supplementary Table 8: Burden of Post-acute Sequelae of COVID-19 individual sequelae in the overall cohort and by age, race, sex, and health 
status in hospitalized COVID-19 
Organ  Sequelae  Overall Age Race 
























































































































































































































































Pulmonary Hypoxemia 18.17 11.15 17.26 24.81 15.8 19.84 
 






























































































































































































































Overall Sex Comorbidity 


































































































































































































































































































































Mental Mood 13.23 13.61 8.15 13.63 13.94 11.06 
 













































































































































Post-acute sequelae were ascertained from 30 days after infection until end of follow-up. 












Supplementary Table 9: Burden of Post-acute Sequelae of COVID-19 individual sequelae in the overall cohort and by age, race, sex, and health 
status in COVID-19 admitted to intensive care 
Organ  Sequelae  Overall Age Race 
























































































































































































































































Pulmonary Hypoxemia 37.73 23.39 41.22 48 29.48 42.24 
 


























































































































































































































Organ  Sequelae  Overall Sex Comorbidity 











































































































































































































































































































Cardiovasc Tachycardia 32.08 32.05 31.06 40.9 39.7 29.8 
 











































































































































































Post-acute sequelae were ascertained from 30 days after infection until end of follow-up. 









Supplementary Table 10: Overall burden of Post-Acute Sequelae of SARS-CoV-2 infection (PASC) after 12 weeks per 1000 persons at 6 months in 
the overall cohort and across care setting (non-hospitalized, hospitalized, and admitted to intensive care during the acute phase of the infection).  
 COVID-19 group 
Adjusted burden per 
1000 persons at 6 
months (95% CI) 
Users of the VHA 
without COVID-19 
Adjusted burden per 
1000 persons at 6 




Adjusted burden per 
1000 persons at 6 































*. Care settings during the first 30 days of infection. 
†. Burden defined as having at least one sequela in excess of users of the Veterans Health 
Administration without COVID-19 after the first 84-days of infection. Burden was estimated 













Supplementary Table 11: Risks and burdens of individual sequela after 12 weeks infection of COVID-19 
Organ  Sequelae  Hazard Ratio 
(95% CI) 
Burden per 1000 persons at 6 months  
(95% CI) 
Cardiovascular  Chest pain 1.43 (1.39, 1.46) 12.61 (11.53, 13.62) 
Arrythmias 1.34 (1.29, 1.38) 6.33 (5.49, 7.12) 
Acute coronary disease 1.17 (1.13, 1.21) 4.78 (3.84, 5.66) 
Tachycardia 1.26 (1.19, 1.33) 2.17 (1.67, 2.65) 
Bradycardia 1.2 (1.14, 1.27) 1.94 (1.37, 2.48) 
Heart failure 1.14 (1.07, 1.21) 1.13 (0.74, 1.52) 
Myocarditis 4.75 (3.22, 6.8) 0.22 (0.14, 0.32) 
Coagulation Thromboembolism 1.68 (1.6, 1.76) 7.44 (6.71, 8.14) 
Dermatologic  Skin rash 1.18 (1.14, 1.22) 3.09 (2.38, 3.78) 
Hair loss 1.83 (1.63, 2.05) 0.27 (0.2, 0.34) 
Endocrine  Hyperlipidemia 1.07 (1.06, 1.09) 14.74 (11.35, 17.85) 
Diabetes mellitus 1.21 (1.17, 1.24) 6.98 (5.82, 8.07) 
Obesity 1.16 (1.13, 1.19) 3.01 (2.52, 3.48) 
Gastrointestinal  GERD 1.18 (1.16, 1.21) 10.44 (9.01, 11.77) 
Constipation 1.22 (1.18, 1.26) 5.16 (4.24, 6.01) 
Diarrhea 1.28 (1.23, 1.33) 4.13 (3.44, 4.79) 
General Fatigue 1.29 (1.25, 1.33) 7.84 (6.86, 8.77) 
Kidney 
 
Chronic kidney disease 1.15 (1.11, 1.20) 5.76 (2.68, 8.68) 
Acute kidney injury 1.16 (1.11, 1.21) 3.02 (2.34, 3.67) 
Mental health  Sleep disorders 1.25 (1.23, 1.28) 17.86 (16.22, 19.39) 
Anxiety 1.12 (1.08, 1.15) 5.24 (3.81, 6.57) 
Depression 1.19 (1.15, 1.22) 5.58 (4.66, 6.46) 
Mood disorder 1.17 (1.14, 1.21) 3.79 (3.05, 4.49) 
Substance abuse 1.11 (1.06, 1.15) 1.27 (0.8, 1.82) 
Musculoskeletal  Muscle weakness 1.3 (1.25, 1.35) 5.32 (4.53, 6.06) 
Joint pain 1.11 (1.08, 1.13) 6.61 (5.18, 7.94) 
Neurologic  Memory problems 1.35 (1.3, 1.4) 5.92 (5.13, 6.67) 
Headache 1.27 (1.23, 1.31) 3.88 (3.31, 4.42) 
Stroke 1.26 (1.19, 1.32) 2.36 (1.8, 2.9) 
Smell problems 3.45 (3.11, 3.8) 1.74 (1.5, 1.98) 
Pulmonary  Shortness of breath 1.72 (1.68, 1.76) 24.13 (22.83, 25.34) 
 
Cough 1.47 (1.42, 1.52) 7.5 (6.68, 8.27) 
Hypoxemia 1.77 (1.67, 1.88) 4.08 (3.62, 4.53) 
Adjusted hazard ratio, adjusted burden per 1000 persons at 6 months of people with COVID-19 compared to users of the 
Veterans Health Administration. All users of the VHA served as the referent category. Outcomes were ascertained from week 12 
after COVID-19 diagnosis until end of follow-up. For each outcome, cohort participants without history of the outcome in past one 




















Supplementary Table 12: Results of negative outcome controls in people with COVID-19 (the overall COVID-19 cohort), and in non-hospitalized, 
hospitalized, and admitted to intensive care for COVID-19. 
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∗.  Care setting during the first 30 days of infection. 
†. The users of the Veterans Health Administration without COVID-19 served as the referent category. Outcomes ascertained after 
















Supplementary Table 13: Definition of each Post-Acute Sequela of SARS-CoV-2 infection (PASC) 
Organ  Sequelae  Definition  
Cardiovascular  Acute coronary disease ICD10 code: I21, I22, I24, I2510, I2511 
Arrythmias ICD10 code: I49, R002, R008, R009 
Bradycardia ICD10 code: R001 
Chest pain ICD10 code: R071, R078, R079 
Heart failure ICD10 code: I5021, I5023, I5031, I5033, I5041, I5043, I50811, I50813 
Myocarditis ICD10 code: B3320, B3321, B3322, B3323, B3324, I400 
Tachycardia ICD10 code: R000 
Coagulation Thromboembolism ICD10 code: I740-I745, I748, I749, I800-I803, I808-I819, I820-I829, I82A-I82C, I2601, I2602, 
I2609, I2690, I2692, I2693, I2694, I2699 
Dermatologic  Hair loss ICD10 code: L659, L658, L63 
Skin rash ICD10 code: R21, B09, L282 
Endocrine  Diabetes mellitus ICD10 code: E08, E09, E10, E11, E13 or HbA1c > 6.5% or use of antihyperglycemics 
Hyperlipidemia Low-density lipoprotein cholesterol>130 mg/dL or Triglycerides>150 mg/dL and use of 
antilipemic agents 
Obesity ICD10 code: E668, E669, E661, E662 or BMI>30 kg/m2 
Gastrointestinal  Constipation ICD10 code: K5900, K5901, K5902, K5903, K5904, K5909 or use of laxatives 
Diarrhea ICD10 code: R197 
GERD ICD10 code: K210, K2100, K2101, K219 
General Fatigue ICD10 code: R531, R5381, R5382, R8383 
Kidney  Acute kidney injury Serum creatine measurement increases more than 50% or increases 0.3 mg/dL  
Chronic kidney disease eGFR measurement < 60 mL/min/1.73m2 
Mental health  Anxiety Use of benzodiazepine derivative sedatives or hypnotics 
Depression ICD10 code: F320, F321, F322, F323, F324, F329 
Mood disorder ICD10 code: F23, F24, F28, F4310, F0631, F0632, F063, F341 
Sleep disorder ICD10 code: F510, F511, F513-F515, F518, F519, G470-G476. G478, G479, R063 
Substance abuse ICD10 code: F10-F19 
Musculoskeletal  Joint pain ICD10 code: M25.5, M79.6, R52, G89, M00-M14 
Muscle weakness ICD10 code: M6281 
Neurologic  Headache ICD10 code: G439, G43C, G440, G442, R51 
Memory problems ICD10 code: R411-R413, F0150, F0151, F0280, F0281, F0390, F0391, F04, F05, F060, 
F068, G309, G3109, G311, G3183-G3185, G3189, G319, G910, G911, G937, G94 
Smell problems ICD10 code: R430, R431, R432, R438, R439 
Stroke ICD10 code: I514, I60-I62, I630-I636, I638, I639 
 
Pulmonary  Cough ICD10 code: R05 or use of antitussives or expectorants 
Hypoxemia ICD10 code: R0902 
Shortness of breath ICD10 code: R0600, R0602, R0609 
Each PASC was defined as occurrence of outcome between 30 days after infection and the end of follow up, within those without the 
occurrence of outcome within one year before infection. 
 
 
 
 
 
